| answer text |
<p>NHS England commissions treatments that have either been approved via the National
Institute for Health and Care Excellence technology appraisal process or NHS England’s
clinical commissioning development process. Service provision will normally be reviewed
at the point that new treatments are approved through either of these two routes.</p><p>Where
additional capacity is required to meet demand, this will be put in place. Developers
of new medicines can apply to the Early Access to Medicines Scheme, Project Orbis
or The Innovative Licensing and Access Pathway to accelerate the time to market for
new products.</p><p>In relation to molecular radiotherapy, linked to the implementation
of the new service specification, NHS England will be undertaking an assessment of
service readiness to implement new technologies.</p>
|
 |
